MGEN News and Press, Miragen Therapeutics Inc. From 02/07/20

BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of ...

BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warran...

Unisys (NYSE: UIS ) +39%  on being acquired by Science Applications International. More news on: Unisys Corporation, Myomo, Inc., China Xiangtai Food Co., Ltd., Stocks on the move, , Read more ...

Myomo (NYSEMKT: MYO ) +93%  on insurance coverage of MyoPro in Germany. More news on: Myomo, Inc., VIVUS, Inc., Camber Energy, Inc., Stocks on the move, , Read more ...

Gainers:  Myomo (NYSEMKT: MYO )  +437% . More news on: Myomo, Inc., Allot Ltd., Phibro Animal Health Corporation, Stocks on the move, , Read more ...

Gainers: OpGen (NASDAQ: OPGN ) +49% . More news on: OpGen, Inc., Insmed Incorporated, Artelo Biosciences, Inc., Stocks on the move, , Read more ...

Gainers:  Datasea (NASDAQ: DTSS ) +81% . More news on: Datasea Inc., Sintx Technologies, Inc., ReTo Eco-Solutions, Inc., Stocks on the move, , Read more ...

Sintx Technologies (NASDAQ: SINT ) +74%  on agreement toward establishing a collaboration framework with Nissin Manufacturing. More news on: Sintx Technologies, Inc., Riot Blockchain, Inc., MYOS RENS Technology Inc., Stocks on the move, , Read more ...

Nano cap miRagen Therapeutics (NASDAQ: MGEN ) jumps  34%  premarket on robust volume on the heels of new Phase 1 data on cobomarsen that will be presented at the T-Cell Lymphoma Forum in La Jolla, CA, that starts today. More news on: Miragen Therapeutics, Inc., Healthcare stock...

Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort - - - Median progression free survival (PFS) of 12.5 months compared with 5.4 months in a historical coh...